In a report released today, Patrick Trucchio from H.C. Wainwright maintained a Buy rating on Invivyd (IVVD – Research Report), with a price ...

H.C. Wainwright analyst Edward White maintained a Hold rating on 60 Degrees Pharmaceuticals, Inc. (SXTP – Research Report) today. The company’s ...

Public bitcoin miners are rushing to build AI business lines, but there’s still room for their original mandate, says this ...

GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (“NK” ...

At this time, I would like to welcome everyone to Harmony Biosciences fourth quarter and full-year 2024 financial results ...

Cash position of €7.5 million as of December 31, 2024 BioChaperone Lispro final dosing of Phase 3 triggered a $10 million revenue recognition, and top-line data are expected in mid-2025 ...

Robert Duggan; Executive Chairman of the Board, Co-Chief Executive Officer; Summit Therapeutics Inc Mahkam Zanganeh; President, Co-Chief Executive Officer, Director; Summit Therapeutics Inc Manmeet ...

"In Q4, we delivered strong marketplace revenue growth, operating leverage and positive Adjusted EBITDA,” said James Miln, Xometry's CFO. "Our record marketplace gross margin of 34.5% and operating ...

Morgan Stanley analyst Patrick Wood lowered the firm’s price target on Bausch + Lomb (BLCO) to $18 from $19 and keeps an Equal Weight rating on ...

There is a broad reckoning in Ukraine: Washington can no longer be relied upon as a supporter. But Kyiv still has agency on the battlefield and can seek increased support from Europe. By ...